Want to join the conversation?
For 2Q16, $STJ said it expects revenue to grow in the range of 1-3% on a comparable constant currency basis compared to a year ago. For FY16, the company continues to expect total revenue to grow in the range of 2-4% on a comparable constant currency basis with currency negatively impacting full-year revenue by approx. $35-55MM.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.